Compass Therapeutics (CMPX) Income from Continuing Operations (2018 - 2026)
Compass Therapeutics (CMPX) reported Income from Continuing Operations of 53211000.0 for Q1 2026, down 219.91% on a YoY basis from 44374959.29 in Q1 2025, and down 194.24% sequentially from 18084000.0 in Q4 2025.
Compass Therapeutics (CMPX) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Compass Therapeutics (CMPX) has 9 years of Income from Continuing Operations data on file, last reported at 53211000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 219.91% year-over-year to 53211000.0; the trailing twelve-month figure through Mar 2026 stood at 126781000.0 (down 111.23% YoY), and the FY2025 full-year result was 151969000.0, down 31.06% from the prior year.
- Income from Continuing Operations slipped to 53211000.0 in Q1 2026, from 18084000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 7162000.0 in Q1 2022 to a low of 53211000.0 in Q1 2026.
- A 5-year average of 16429882.35 and a median of 13076000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations grew 16.79% in 2023 and sank 219.91% in 2026, its largest moves.
- Tracing CMPX's Income from Continuing Operations over 5 years: stood at 11594000.0 in 2022, then retreated by 15.71% to 13415000.0 in 2023, then slipped by 25.61% to 16850000.0 in 2024, then retreated by 7.32% to 18084000.0 in 2025, then sank by 194.24% to 53211000.0 in 2026.
- Business Quant data shows CMPX's Income from Continuing Operations at 53211000.0 in Q1 2026, 18084000.0 in Q4 2025, and 27374000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Compass Therapeutics | 388.64 Mn | 193.96 Mn | - | -53.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.21 Mn |
| Dec 31, 2025 | -18.08 Mn |
| Sep 30, 2025 | -27.37 Mn |
| Jun 30, 2025 | -28.11 Mn |
| Mar 31, 2025 | -16.63 Mn |
| Dec 31, 2024 | -16.85 Mn |
| Sep 30, 2024 | -13.46 Mn |
| Jun 30, 2024 | -13.08 Mn |
| Mar 31, 2024 | -10.79 Mn |
| Dec 31, 2023 | -13.42 Mn |
| Sep 30, 2023 | -9.96 Mn |
| Jun 30, 2023 | -11.28 Mn |
| Mar 31, 2023 | -7.84 Mn |
| Dec 31, 2022 | -11.59 Mn |
| Sep 30, 2022 | -11.98 Mn |
| Jun 30, 2022 | -8.49 Mn |
| Mar 31, 2022 | -7.16 Mn |
| Dec 31, 2021 | -12.98 Mn |
| Sep 30, 2021 | -5.98 Mn |
| Mar 31, 2021 | -7.42 Mn |